GLP-1s

Sales & Marketing

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Patients

At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.

R&D

R&D

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

News

Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

R&D